To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of inhaled AZD8683

Exclusion Criteria

• - History or presence of gastrointestinal, pulmonary, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
• - Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the investigational product
• - Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:
• * Systolic blood pressure >140 mm Hg
• * Diastolic blood pressure >90 mm Hg
• * Heart rate <40 or >85 beats per minute Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG. This includes subjects with any of the following:
• * PR(PQ) interval prolongation >200 ms or dropped beats (single non conducted P-waves) based on screening or Prolonged QTcF >450 ms or shortened QTcF <340 ms or family history of long QT syndrome